

Introduction & Notes re: RIVAP Annual Assessment Setting Workbook

Assessment Calculations for RIVAP's seventh full year of operations (12 months starting July 1, 2022)

Note: This KidsVax®'s final documentation for rates approved by the RI Department of Health in April, 2022

01. This workbook follows the naming conventions of having each tab or sheet begin with a letter (i.e., "a." through "d."), and each cell within each sheet be identified by row number (e.g., "01.") and column letter (e.g., "A"). So, to facilitate reference while collaborating via conference phone, users can refer to any single number, for example the new child vaccine calculated assessment rate, by a combination of the above. For that key number, the reference is "a.17.B".
02. The first assessment payment with the SFY23 rate will be due on July 30, 2022 for the assessment accounting months of Jul-Sep 2022 (i.e., the first quarter of the state fiscal year – SFY23). Assessments are due 30 days after the end of the quarter. Thus the assessment due on July 30, 2022 uses the measuring months of April - June 2022.
03. The primary spreadsheet for the work is the assessment calculation worksheet, worksheet a. The other sheets are intended to be reference or to develop background data in specific areas for the work. Key data for developing the primary funding target is on sheet b. which contains data supplied by the Rhode Island Department of Health (RIDOH) for the vaccine funding needs. Key numbers from a subsidiary sheet rolled into the main assessment sheet generally are shaded in yellow.
04. Key control points expected to be subject to policy decisions are coded in red font and shaded green. On the protected version of the sheets, cells not shaded green may be locked out to reduce the likelihood of user error. The password used is "RIVAP" -- this is not a matter of confidentiality, but rather to reduce error. Users who want to unlock the sheets for any reason are welcome to do so.
05. RIDOH reserves the right to adjust the assumptions which guide the assessment level. RIDOH may also determine to adjust the assessment setting process itself or this workbook structure at any time. It is anticipated going forward that new assessment rates will become effective on July 1 each year based upon calculations targeted to be completed in each immediately preceding April.

Rhode Island Vaccine Assessment Program Assessment Calculation Worksheet

Column →	A	B	C	D	E	F	G
	CHILDREN			ADULTS			
Line ↓	Prior (2021/22)	SFY 2022/23		Prior (2021/22)	SFY 2022/23		Comments
A. Preliminary Vaccine Cost Estimates & Budget Parameters							
01.	\$16,108,108	\$17,116,830		\$18,154,830	\$19,534,091		Estimated vaccine costs
02.		\$0	0.0%	\$344,942	\$781,364	4.0%	Provision for vaccine cost increase
03.	\$1,950,959	\$2,038,967	15.0%	\$1,114,973	\$1,012,887	5.9%	Program operations costs (fluctuates based on program need)
04.	\$210,835	\$303,406		\$228,812	\$341,957		RI Vaccine Assessment Program (RIVAP) Funding operations
05.	\$1,607,447	\$1,561,638	10.0%	\$1,999,426	\$2,285,572	10.0%	State of RI Administrative Fee (DOA Cost Recovery)
06.	\$19,877,350	\$21,020,841		\$21,842,982	\$23,955,871		Net RIVAP Funds Needed by RIDOH
B. Assessable Covered Lives Estimates							
07.	90,663	88,104		524,388	536,264		Self-Reported Contribution Enrollees (sheet c.)
08.	0.00%	0	0.0%	0.00%	0	0.0%	Leakage (unknown insurer, out of reach entity, etc.)
09.	90,663	88,104		524,388	536,264		Assessable lives actually paying
C. Assessment Calculation							
10.	\$19,877,350	\$ 21,020,841		\$21,842,982	\$ 23,955,871		Costs to be raised
11.	\$532,576	\$ 608,386		\$129,854	\$ 141,509		TRICARE Revenue
12.	\$4,567,476	\$4,864,801	25.0%	\$4,960,889	\$5,417,575	25.0%	Working Capital Reserve (3 months of reserves)
13.	\$5,520,000	\$1,025,000		\$8,950,000	\$0		Additional COVID-19 Reserve
14.	-\$13,357,778	-\$10,685,874		-\$15,629,760	-\$6,376,218		RIVAP carryforward
15.	\$16,074,471	\$15,616,383		\$19,994,257	\$22,855,718		Total Assessment Billed
D. Per Assessable Covered Life Assessment							
16.	\$177.30	\$ 177.25		\$38.13	\$ 42.62		Annual Assessment per contribution enrollee
17.	\$14.78	\$ 14.78	0.0%	\$ 3.18	\$ 3.56	11.9%	Monthly Assessment per enrollee calculated/% Change
18.	\$14.78	\$ 14.78	0.0%	\$ 3.18	\$ 3.56	11.9%	Monthly Assessment per enrollee final/% Change
19.	\$18.27	\$19.88	8.8%	\$3.47	\$3.72	7.2%	Run Rate Monthly Assessment per enrollee /% change in RR
20.	\$19.18	\$20.88	41.2%	\$3.64	\$3.91	9.8%	Preliminary Assessment projection/Anticipated Increase
F. Overall Program Metrics							
21.	23.4%	22.8%		18.1%	17.9%		Total non-vaccine costs as % of RIDOH vaccine costs
22.	38.3%	39.7%		40.1%	28.7%		Private purchase costs above RIDOH vaccine costs

Notes:

- ¹ RIDOH costs raised via assessments pursuant to statutory authorization. (Capped at 15% -- budget is set by RIDOH outside of this program.)
- ² KidsVax comprehensive administrative services, executive director and technology fee.
- ³ % of Revenues Raised as set by the Rhode Island Department of Administration.
- ⁴ The CDC contract prices change dates are 4/1 for childhood vaccines and 7/1 for adult vaccines. The child price increase is 0 on Line 2 because RIDOH anticipates purchasing vaccines administered in April-June 2023 in March 2023, at April 2022 prices. All childhood vaccine cost projections are based on April 2022 CDC pricing. The line 2 provision for cost increases is applied for 12 months for adult vaccines in order to estimate July 2022 CDC prices.
- ⁵ Carryforward cash amounts, if any, will be applied to reduce subsequent years' assessments (see line 13).
- ⁶ Preliminary projection: This is the normalized assessment rate and one additional year of inflation.
- ⁷ TRICARE is not in compliance with RIDOH's assessment system. Its non-compliance is in dispute. The amount shown is a good faith estimate of the minimum TRICARE is expected to pay in SFY 2022/2023 based upon its payments in 2021/2022.

SFY2023 Vaccine Budget		Vaccine Information					Current PO Values				
Tab	Vaccine	NDC	CDC Contract	Doses per unit	Units per box	FET Anti-gens	Dose Qty	Cost p/dose	FET p/dose	Ext. Cost p/dose	PO Value
30	DT	49281-0225-10	Sole Source	1	10	2	0	\$ 55.750	\$1.50	\$ 57.250	\$0
3	IPOL (EIPV)	49281-0860-10	2-2021-10573	10	1	1	1,400	\$ 14.363	\$0.75	\$ 15.113	\$21,158
5	MenQuadfi MCV5	49281-0590-05	2-2021-10576	1	5	1	13,500	\$ 103.968	\$0.75	\$ 104.718	\$1,413,693
6	TD	13533-0131-01	2-2021-10578	1	10	2	650	\$ 15.857	\$1.50	\$ 17.357	\$11,282
10	Prevnar 13 (PCV 13)	00005-1971-02	2-202110579	1	10	1	21,500	\$ 157.430	\$0.75	\$ 158.180	\$3,400,870
8	Bexsero	58160-0976-20	2-202110573	1	10	1	8,800	\$ 134.247	\$0.75	\$ 134.997	\$1,187,974
11	Infanrix (DTaP)	58160-0810-52	2-202110573	1	10	3	6,000	\$ 18.118	\$2.25	\$ 20.368	\$122,208
12	Vaxelis	63361-0243-15	2-202110573	1	10	5	15,800	\$ 91.320	\$3.75	\$ 95.070	\$1,502,106
13	Kinrix (DTaP/IPV)	58160-0812-52	2-202110573	1	10	4	6,100	\$ 42.269	\$3.00	\$ 45.269	\$276,141
14	Havrix (Hep A)	58160-0825-52	2-202110573	1	10	1	17,000	\$ 21.603	\$0.75	\$ 22.353	\$380,001
15	Engerix-B (Hep B)	58160-0820-52	2-202110573	1	10	1	6,850	\$ 15.520	\$0.75	\$ 16.270	\$111,450
18	Rotarix (Rota)	58160-0854-52	2-202110573	1	10	1	10,900	\$ 101.654	\$0.75	\$ 102.404	\$1,116,204
19	Boostrix (TDaP)	58160-0842-52	2-202110573	1	10	3	8,000	\$ 32.772	\$2.25	\$ 35.022	\$280,176
22	PedvaxHib (Hib)	00006-4897-00	2-2021-10575	1	10	1	8,200	\$ 14.070	\$0.75	\$ 14.820	\$121,524
9	Gardasil (HPV9)	00006-4121-02	2-2021-10575	1	10	1	20,000	\$ 207.300	\$0.75	\$ 208.050	\$4,161,000
24	MMR II	00006-4681-00	2-2021-10575	1	10	3	6,750	\$ 21.420	\$2.25	\$ 23.670	\$159,773
25	Proquad MMRV	00006-4171-00	2-2021-10575	1	10	4	6,550	\$ 150.507	\$3.00	\$ 153.507	\$1,005,471
26	Pneumovax23 (Pedi)	00006-4837-03	2-2021-10575	1	10	0	400	\$ 65.800	\$0.00	\$ 65.800	\$26,320
28	Varivax	00006-4827-00	2-2021-10575	1	10	1	6,800	\$ 121.920	\$0.75	\$ 122.670	\$834,156
23	Menveo	58160-0955-09	2-202110573	1	5	1	200	\$ 101.796	\$0.75	\$ 102.546	\$20,509
Influenza	Fluarix 0.5ml (6 mos -18 yrs)	58160-0890-52					25,850	\$ 13.910	\$ 0.75	\$14.66	\$378,961
	Flulaval 0.5ml (6 mos -18 yrs)	19515-0808-52					25,850	\$ 13.910	\$ 0.75	\$14.66	\$378,961
	FluMist 0.5ml (2-18 yrs)	66019-0309-10					3,520	\$ 18.130	\$ 0.75	\$18.88	\$66,458
	Flucelvax (6 months - 18 yrs)	70461-0322-03					7,050	\$ 19.170	\$ 0.75	\$19.92	\$140,436
Total Pediatric							227,670	<= Doses		Cost =>	\$17,116,830
29	Pneumovax23 (PPV23 - Ad)	00006-4837-03	2-2021-11354	1	10	0	35,000	\$ 74.503	\$0.00	\$ 74.50	\$2,607,605
32	Gardisal (HPV9 - Ad)	00006-4121-02	2-2021-11354	1	10	1	5,000	\$ 159.023	\$0.75	\$ 159.77	\$798,865
20	MMR II (MMR - Ad)	00006-4681-00	2-2021-11354	1	10	3	7,000	\$ 51.679	\$2.25	\$ 53.93	\$377,503
21	Varivax (Var - Ad)	00006-4827-00	2-2021-11354	1	10	1	2,300	\$ 93.635	\$0.75	\$ 94.39	\$217,086
16	Bexsero (MenB)	58160-0976-20	2-2021-11353	1	10	1	3,000	\$ 110.648	\$0.75	\$ 111.40	\$334,194
31	Twinrix (Hep AB)	58160-0815-52	2-2021-11353	1	10	2	600	\$ 62.443	\$1.50	\$ 62.44	\$37,466
17	Prevnar 20	00005-1971-02	2-2021-11355	1	10	1	15,000	\$ 172.940	\$0.75	\$ 173.69	\$2,605,350
27	(Td - Ad)	13533-0131-01	2-2021-11352	1	10	2	6,500	\$ 14.971	\$1.50	\$ 16.47	\$107,062
7	Adacel (Tdap - Ad)	49281-0400-20	2-2021-11356	1	5	3	63,000	\$ 24.732	\$2.25	\$ 26.98	\$1,699,866
1	Menactra (MCV4 - Ad)	49281-0589-05	2-2021-11356	1	5	1	2,700	\$ 79.978	\$0.75	\$ 80.73	\$217,966
2	HepIsav-B (Hep B-Ad)	43528-0003-05	2-2021-11351	1	5	1	8,500	\$ 74.190	\$0.75	\$ 74.94	\$636,990
4	Havrix (Hep A)	58160-0826-52	2-2021-11353	1	10	1	5,500	\$ 35.885	\$0.75	\$ 36.64	\$201,493
Influenza	Fluzone PF 0.5ml (19+ yrs)	49281-0422-50					125,000	\$ 13.878	\$ 0.75	\$ 14.63	\$1,828,500
	Flucelvax PF 0.5ml (19+ yrs)	70461-0322-03					85,390	\$ 17.320	\$ 0.75	\$ 18.07	\$1,542,997
	Fluzone HD	49281-0122-65					55,000	\$ 58.000	\$ 0.75	\$ 58.75	\$3,231,250
	Fluad (65+ yrs)	70461-0122-03					55,000	\$ 55.430	\$ 0.75	\$ 56.18	\$3,089,900
Total Adult							474,490	<= Doses		Cost =>	\$19,534,091.20

b. Vaccine Projection Worksheet

Rhode Island Vaccine Assessment Program

Pediatric Vaccine Projection Summary

SFY 2022/23

	Cost Per Dose	Doses	Total Cost
Prior Year Projected	\$65.12	247,350	\$16,108,108
Fiscal Year Projected	\$75.18	227,670	\$17,116,830
Variance	\$10.06	-19,680	\$1,008,722
% Variance	15.4%	-8.0%	6.3%

Projection Change Drivers:

The 15.4% cost per dose increase is in part due to removing lower cost flu vaccines.

Holding the vaccine mix constant, the increase per dose is 8%. This is still high relative to the more typical 3-4% CDC price increase.

Vaxelis replaced Pediatric (DTaP/Hep B/IPV). The result was a 52% cost increase for that vaccine. Removing this vaccine lowers the 8% to about 5%.

Due to the change to Vaxelis, there was a reduction in the number of PedvaxHIB (in half) doses , since Vaxelis is used for the first two doses.

The rest of the decline in doses is due to reduced flu doses. The flu dose reduction is due to an over projection in flu vaccines in the prior year.

Adult Vaccine Projection Summary

SFY 2022/23

	Cost Per Dose	Doses	Total Cost
Prior Year Projected	\$35.22	515,400	\$18,154,830
Fiscal Year Projected	\$41.17	474,490	\$19,534,091
Variance	\$5.94	-40,910	\$1,379,262
% Variance	16.9%	-7.9%	7.6%

Projection Change Drivers:

The 16.9% cost per dose increase, is in part due to removing lower cost flu vaccines.

Holding the vaccine mix constant, lowers the increase per dose to 11%. This is high relative to a more typical 3-4% CDC price increase.

The 11% is due in part to the CDC replacing Prevnar 13 with Prevnar 20, and the cost per dose going up 32%. Prevnar 13 is no longer available.

There are several other vaccines with double digit price per dose increases. The increase without the one time Prevnar change is about 8%.

The decline in the number of doses is due to reduced flu doses. The flu dose reduction is due to an over projection in flu vaccines in the prior year.

Rhode Island Vaccine Assessment Program
Estimated Contribution Enrollees For SFY 2023 Assessment Calculation

Contribution Enrollees reported to KV by quarter:

Column → Line ↓	A	B	C		D	E	F	G	H		I
	Assessment Quarter	Membership Period	Quarter Kids		Adults	Kids	Monthly Average Adults	Total	Monthly Average (using 12 months) Kids		Adults
01.	FY 20 Q4	1/2020-3/2020	278,082	1,550,257	92,694	516,752	609,446	92,318	517,247		
02.	FY 21 Q1	4/2020-6/2020	274,091	1,571,497	91,364	523,832	615,196	92,012	517,679		
03.	FY 21 Q2	7/2020-9/2020	269,937	1,582,369	89,979	527,456	617,435	91,443	519,902		
04.	FY 21 Q3	10/2020-12/2020	265,850	1,588,530	88,617	529,510	618,127	90,663	524,388		
05.	FY 21 Q4	1/2021-3/2021	266,783	1,595,943	88,928	531,981	620,909	89,722	528,195		
06.	FY 22 Q1	4/2021-6/2021	263,657	1,597,397	87,886	532,466	620,351	88,852	530,353		
07.	FY 22 Q2	7/2021-9/2021	263,830	1,616,558	87,943	538,853	626,796	88,343	533,202		
08.	FY 22 Q3	10/2021-12/2021	262,982	1,625,271	87,661	541,757	629,418	88,104	536,264		
09.	Most Recent Year Average					88,104	536,264				
10.	Most Recent Year Max					88,928	541,757			<u>Variance</u> Kids	Adults
11.	Most Recent year Min					87,661	531,981			1.4%	1.8%